NanoViricides (NYSE-A:NNVC) CEO Dr Anil Diwan joined Steve Darling from Proactive to share exciting updates on their antiviral drug candidate, NV 387, in a recent interview. The drug, developed in response to the COVID-19 pandemic, demonstrated exceptional safety in clinical trials, even at the highest dose levels, with no adverse events reported. The unique mechanism of action involves mimicking a cell membrane, encapsulating and blocking the virus.
The clinical trials involved both oral tablets and oral gummies, catering to various age groups, including pediatrics. NV 387 exhibited broad-spectrum activity against multiple strains of coronaviruses, showcasing effectiveness 10 times greater than remdesivir in preclinical studies. Beyond COVID-19, the drug also displayed promising results against respiratory syncytial virus (RSV), offering a potential solution for infants and seniors where existing treatments like ribavirin may be contraindicated due to side effects.
Dr. Diwan highlighted the drug's versatility, suggesting applications against other respiratory viruses and even biodefense-related infections like smallpox. The ongoing clinical trial progress and positive results position NanoViricides at the forefront of antiviral drug development, marking a significant milestone in their journey from preclinical research since 2005 to clinical trials.